Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450008 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00450008: Clinical Trial Phase 2 study, sponsored by The Methodist Hospital Research Institute.
NCT00450008 is a Phase 2 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00450008, a Phase 2 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
Primary Outcome
PI relocated, no data currently available
Interventions
- DRUG docetaxel
- DRUG GM-CSF
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Why NCT00450008 stopped before completion
NCT00450008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00450008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00450008 about?
NCT00450008 is a clinical study titled "Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer". The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
What is the current status of trial NCT00450008?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00450008?
The interventions under investigation include: docetaxel (DRUG), GM-CSF (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00450008?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00450008's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia